Valensa International introduced a new innovation, while educating the industry about achieving US Pharmacopeia Dietary Ingredient Verification Program (USP DIVP) status during a first-time panel discussion at the SupplySide West exhibition in Las Vegas, October 15-19. During the convention, which attracted an estimated 30,000 people from the industry, Valensa introduced a new form of Zanthin® Astaxanthin with joint, cardiovascular and eye health benefits, to give consumers more dosage options, like a liquid power shot developed in collaboration with Virun. Valensa’s Zanthin® was also featured in a white paper, explaining how Valensa is evolving its astaxanthin efficacy.
While the new innovation received excellent response from the market, the week’s highlight was hosting a first-time panel with special guest Edward Wyszumiala from USP. The panel topic, “Ensuring Purity and Potency Through the USP Verification. A Case Study: Saw Palmetto,” gave attendees insight into the process for obtaining USP verification, which indicates a product’s level of safety and authenticity, to combat less effective and adulterated saw palmetto products.
Following the panel, several editors from the industry asked for more information, including Alternative Medicine magazine, Vitamin Retailer, and Nutraceuticals Business Review.
USP’s DIVP tests dietary ingredients, audits manufacturing practices and reviews documentation before the manufacturer earns the use of the USP Verified Mark. Having received recognition from USP, Valensa International was also added to USP’s website, a resource for finished product manufacturers to identify ingredient manufacturers who have earned the right to use the USP mark.
Click here for more information about USP’s Dietary Ingredient Verification Program and the process by which Valensa International was awarded this certification and more information about USP at www.usp.org.
For more information: Steve Malone, s.malone@valensa.com, (352) 357-2004.
SupplySide West Photos:
